<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135275</url>
  </required_header>
  <id_info>
    <org_study_id>MULTISTARS_USZ</org_study_id>
    <nct_id>NCT03135275</nct_id>
  </id_info>
  <brief_title>MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial</brief_title>
  <acronym>MULTISTARS AMI</acronym>
  <official_title>MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction - The MULTISTARS AMI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to compare, in patients presenting with ST elevation
      myocardial infarction (STEMI) and multi-vessel disease (MVD), the safety and efficacy of
      immediate complete primary percutaneous coronary intervention (PCI) of all target vessels
      versus culprit vessel only revascularization, followed by staged PCI (within minimal 19 and
      maximal 45 days) of all target vessels, in a non-inferiority trial, using a third generation
      biodegradable-polymer everolimus-eluting stent (Synergy™).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An investigator-initiated, randomized, multicenter, non-blinded study of consecutive patients
      presenting with STEMI and MVD in stable hemodynamic conditions, undergoing after successful
      PCI of the culprit lesion either (1:1 randomization) immediate revascularization during the
      index procedure of all additional target lesions or staged PCI of additional target lesions
      (within 19-45 days) using the Boston Scientific Synergy™ stent.

      The goal of this trial is to compare two treatment strategies that are currently performed in
      clinical practice: complete immediate revascularization versus staged revascularization in
      patients with STEMI with MVD, using in both groups the Synergy™ stent.

      Patients randomized to complete immediate revascularization will have treated during the
      index procedure, after the revascularization of the culprit lesion responsable for the STEMI,
      the other significant coronary stenosis.

      Patients randomized to staged revascularization will have treated during the index admission
      only the culprit lesion and they will be hospitalized again after 19-45 days to complete the
      revascularization on the other significant coronary lesions.

      For both groups lesion are defined significant when causing a ≥70% diameter stenosis by
      visual estimation in at least two projections, with current on line state of the art
      angiographic equipment of the participating centers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite endpoint of all cause of death, non-fatal myocardial infarction, unplanned ischemia-driven coronary revascularization</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All revascularizations</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (Q-wave and non-Q-wave)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non cardiac death</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause of death</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or myocardial infarction</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause of death or myocardial infarction</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis or acute renal insufficiency</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding (BARC classification)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoint of all cause of death, non-fatal myocardial infarction, unplanned ischemia-driven coronary revascularization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoint of all cause of death, non-fatal myocardial infarction, unplanned ischemia-driven coronary revascularization</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite endpoint of all cause of death, non-fatal myocardial infarction, unplanned ischemia-driven coronary revascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>1-year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <condition>Multivessel Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Staged complete PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on the other significant coronary lesions. All the PCIs will be performed with Synergy™ stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate complete PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure, the other significant coronary stenosis. All the PCIs will be performed with Synergy™ stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Staged complete PCI</intervention_name>
    <description>During the index procedure patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of ther other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent implantation.</description>
    <arm_group_label>Staged complete PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immediate complete PCI</intervention_name>
    <description>During the index procedure patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.</description>
    <arm_group_label>Immediate complete PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy™ stent</intervention_name>
    <description>Bioabsorbable Polymer Drug-Eluting Stent</description>
    <arm_group_label>Staged complete PCI</arm_group_label>
    <arm_group_label>Immediate complete PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed

          -  Age ≥ 18 years

          -  Patient with spontaneous acute ST elevation myocardial infarction presenting within 24
             hours of symptom onset

          -  General suitable for percutaneous coronary intervention from femoral or radial access

          -  Coronary anatomy suitable for complete percutaneous revascularization with Synergy™
             stent implantation

          -  Identifiable culprit lesion/artery

          -  A coronary stenosis ≥ 70% in at least two projections, in a vessel with a lumen
             diameter &gt;= 2.25 - &lt;= 5.75 mm, other than the culprit artery (The severity of the
             stenosis should be based on visual estimation, with current on line state of the art
             angiographic equipment of the participating centers and after a mandatory dose of
             50-200 mcg intracoronary of nitroglycerine. The additional use of anatomic
             (intravascular ultrasound or optical coherence tomography) or functional (fractional
             flow reserve) imaging modalities is left to the operator's discretion.

          -  TIMI Flow 3 or consistent TIMI flow 2 after revascularization of the culprit artery

          -  Stable hemodynamics at the end of the culprit coronary revascularization

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Cardiogenic shock

          -  Prolonged resuscitation &gt;10 mins

          -  General unsuitability for percutaneous coronary intervention

          -  Need for emergency coronary artery bypass graft

          -  Previous coronary artery bypass graft

          -  Planned hybrid revascularization

          -  Coronary dissection

          -  STEMI due to stent thrombosis

          -  Severe mechanical complication of acute MI

          -  Severe renal failure (eGFR &lt; 30 mL/min, calculated with CKD-EPI creatinine equation)
             or dialysis

          -  Chronic total occlusion of a major coronary artery

          -  Left main stem stenosis ≥ 50% or left main stem equivalent (ostial left anterior
             descending and ostial circumflex stenosis ≥ 70%)

          -  Planned coronary, cerebrovascular, or peripheral arterial revascularization

          -  Planned cardiac or major surgery

          -  Any contraindications for dual antiplatelet therapy with aspirin and a P2Y12
             inhibitors (clopidogrel, ticagrelor, prasugrel) for at least 90 days. Dual
             antiplatelet therapy should be continued as per ESC guidelines and preferably for one
             year in all patients

          -  Known pregnancy at the time of inclusion

          -  Known allergy to everolimus

          -  Participation in another clinical study with an investigational product

          -  Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willibald Maier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Lüscher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Willibald Maier, MD</last_name>
    <email>willibald.maier@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giulia Magnani, MD, PhD</last_name>
    <email>giulia.magnani@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zürich, Cardiology Department</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willibald Maier, MD</last_name>
      <email>willibald.maier@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Giulia Magnani, MD, PhD</last_name>
      <email>giulia.magnani@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Willibald Maier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013 Sep 19;369(12):1115-23. doi: 10.1056/NEJMoa1305520. Epub 2013 Sep 1.</citation>
    <PMID>23991625</PMID>
  </results_reference>
  <results_reference>
    <citation>Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015 Mar 17;65(10):963-72. doi: 10.1016/j.jacc.2014.12.038.</citation>
    <PMID>25766941</PMID>
  </results_reference>
  <results_reference>
    <citation>Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015 Aug 15;386(9994):665-71.</citation>
    <PMID>26347918</PMID>
  </results_reference>
  <results_reference>
    <citation>Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW; HORIZONS-AMI Trial Investigators. Prognostic impact of staged versus &quot;one-time&quot; multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011 Aug 9;58(7):704-11. doi: 10.1016/j.jacc.2011.02.071.</citation>
    <PMID>21816305</PMID>
  </results_reference>
  <results_reference>
    <citation>Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2009 Aug 15;104(4):507-13. doi: 10.1016/j.amjcard.2009.04.016. Epub 2009 Jun 18.</citation>
    <PMID>19660603</PMID>
  </results_reference>
  <results_reference>
    <citation>Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011 Feb;32(4):396-403. doi: 10.1093/eurheartj/ehq410. Epub 2010 Nov 30. Review.</citation>
    <PMID>21118854</PMID>
  </results_reference>
  <results_reference>
    <citation>Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24.</citation>
    <PMID>22922416</PMID>
  </results_reference>
  <results_reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </results_reference>
  <results_reference>
    <citation>Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11.</citation>
    <PMID>24332419</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ST-elevation Myocardial Infarction</keyword>
  <keyword>Multivessel coronary disease</keyword>
  <keyword>Immediate complete coronary revascularization</keyword>
  <keyword>Staged complete coronary revascularization</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Biodegradable-polymer everolimus-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

